• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

溶血尿毒综合征中C3和B因子的降解产物

Breakdown products of C3 and factor B in hemolytic-uremic syndrome.

作者信息

Kim Y, Miller K, Michael A F

出版信息

J Lab Clin Med. 1977 Apr;89(4):845-50.

PMID:845484
Abstract

Serum concentrations of Clq, C4, C3, and Factor B but not properdin were significantly decreased in patients with HUS compared to values in normal control subjects (p value less than 0.01). Sera from 13 HUS patients obtained early after the onset of the disease showed breakdown products of Factor B (Ba, Bb) by immunoelectrophoresis; 12 of these sera showed C3 breakdown products (C3c, C3d). Sera from seven patients studied 1 month to 3 years later no longer demonstrated any breakdown products of Factor B or C3. These data suggest that the complemented system is activate in HUS. The concept that immunological mechanisms play a major role in this disease is additionally supported by the occurrence of IgM, C3, and fibrin in glomeruli and renal vessels.

摘要

与正常对照受试者相比,溶血尿毒综合征(HUS)患者血清中Clq、C4、C3和B因子的浓度显著降低,但备解素浓度无显著变化(p值小于0.01)。13例HUS患者在疾病发作后早期采集的血清经免疫电泳显示有B因子的裂解产物(Ba、Bb);其中12份血清显示有C3裂解产物(C3c、C3d)。对7例患者在1个月至3年后进行研究,其血清不再显示B因子或C3的任何裂解产物。这些数据表明补体系统在HUS中被激活。肾小球和肾血管中出现IgM、C3和纤维蛋白,进一步支持了免疫机制在该疾病中起主要作用的观点。

相似文献

1
Breakdown products of C3 and factor B in hemolytic-uremic syndrome.溶血尿毒综合征中C3和B因子的降解产物
J Lab Clin Med. 1977 Apr;89(4):845-50.
2
Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.系统性红斑狼疮患者以及膜增生性或其他肾小球肾炎患者血浆中的补体裂解产物。
J Clin Invest. 1975 Jul;56(1):165-76. doi: 10.1172/JCI108065.
3
The complement system in hemolytic-uremic syndrome in childhood.儿童溶血尿毒综合征中的补体系统。
Clin Nephrol. 1980 Apr;13(4):168-71.
4
Hemolytic uremic syndrome with hypocomplementemia, serum C3NeF, and glomerular deposits of C3.伴有低补体血症、血清C3NeF及C3肾小球沉积物的溶血性尿毒症综合征
Arch Pathol Lab Med. 1977 Jul;101(7):357-61.
5
Immunopathology of the end-stage kidney. Immunoglobulin and complement component deposition in nonimmune disease.终末期肾脏的免疫病理学。免疫球蛋白和补体成分在非免疫性疾病中的沉积。
Am J Pathol. 1976 Jul;84(1):149-62.
6
Renal histopathology in the hemolytic-uremic syndrome following shigellosis.志贺菌病后溶血尿毒综合征的肾脏组织病理学
Clin Nephrol. 1984 Feb;21(2):126-33.
7
C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.风湿性疾病中的C3b灭活剂。通过放射免疫扩散法以及对备解素途径C3转化酶形成的抑制作用进行测量。
J Clin Invest. 1976 Jun;57(6):1554-63. doi: 10.1172/JCI108426.
8
C3, C4, factor B and HLA-DR alpha mRNA expression in renal biopsy specimens from patients with IgA nephropathy.IgA肾病患者肾活检标本中C3、C4、B因子和HLA-DRα mRNA表达
Immunology. 1995 Dec;86(4):575-83.
9
Hemolytic uremic syndrome with hypocomplementemia and deposits of IgM and C3 in the involved renal tissue.伴有低补体血症且在受累肾组织中有IgM和C3沉积的溶血性尿毒症综合征。
Clin Nephrol. 1981 Oct;16(4):193-9.
10
Possible C1q bypass loop activation in the haemolytic uraemic syndrome.溶血尿毒综合征中可能存在的C1q旁路循环激活。
Clin Exp Immunol. 1979 Jan;35(1):107-11.

引用本文的文献

1
Friend or foe: assessing the value of animal models for facilitating clinical breakthroughs in complement research.敌友之间:评估动物模型在推动补体研究临床突破方面的价值。
J Clin Invest. 2025 Jun 16;135(12). doi: 10.1172/JCI188347.
2
Complement biosensors identify a classical pathway stimulus in complement-mediated thrombotic microangiopathy.补体生物传感器可识别补体介导的血栓性微血管病中的经典途径刺激物。
Blood. 2024 Dec 12;144(24):2528-2545. doi: 10.1182/blood.2024025850.
3
Shiga toxin targets the podocyte causing hemolytic uremic syndrome through endothelial complement activation.
志贺毒素通过内皮补体激活靶向足细胞,引起溶血尿毒综合征。
Med. 2023 Nov 10;4(11):761-777.e8. doi: 10.1016/j.medj.2023.09.002. Epub 2023 Oct 19.
4
Severe Neurological Involvement in an Adult with Shiga Toxin-Producing -Hemolytic Uremic Syndrome Treated with Eculizumab.接受依库珠单抗治疗的产志贺毒素成人溶血尿毒综合征患者的严重神经系统受累情况
Case Rep Nephrol Dial. 2023 Jan 27;13(1):7-14. doi: 10.1159/000528893. eCollection 2023 Jan-Dec.
5
HUS with mutations in CFH and STEC infection treated with eculizumab in a 4-year-old girl.一名 4 岁女孩因 CFH 和产志贺毒素大肠杆菌感染的 HUS 接受依库珠单抗治疗。
Pediatr Nephrol. 2023 Apr;38(4):1195-1203. doi: 10.1007/s00467-022-05694-z. Epub 2022 Aug 15.
6
MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab.血栓性微血管病中 MASP2 水平升高:与微血管内皮细胞损伤相关,并被抗 MASP2 抗体 narsoplimab 抑制。
Clin Exp Immunol. 2021 Jan;203(1):96-104. doi: 10.1111/cei.13497. Epub 2020 Aug 5.
7
Hemolytic Uremic Syndrome With Severe Neurologic Complications in an Adult.一名成人患有伴有严重神经系统并发症的溶血性尿毒症综合征。
Fed Pract. 2019 Jun;36(Suppl 4):S36-S41.
8
Outbreak of Shiga toxin-producing Escherichia-coli-associated hemolytic uremic syndrome in Istanbul in 2015: outcome and experience with eculizumab.2015 年伊斯坦布尔肠出血性大肠杆菌 O104:H4 感染爆发相关溶血尿毒综合征:结局和依库珠单抗的应用经验。
Pediatr Nephrol. 2018 Dec;33(12):2371-2381. doi: 10.1007/s00467-018-4033-0. Epub 2018 Aug 29.
9
Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome.依库珠单抗治疗志贺毒素溶血尿毒综合征。
Pediatr Nephrol. 2019 Sep;34(9):1485-1492. doi: 10.1007/s00467-018-4025-0. Epub 2018 Jul 30.
10
Activation of the alternative pathway of complement during the acute phase of typical haemolytic uraemic syndrome.典型溶血尿毒综合征急性期补体替代途径的激活。
Clin Exp Immunol. 2015 Jul;181(1):118-25. doi: 10.1111/cei.12601. Epub 2015 May 5.